^Wiesfeld AC, Crijns HJ, Bergstrand RH, Almgren O, Hillege HL, Lie KI (1993). "Torsades de pointes with Almokalant, a new class III antiarrhythmic drug". American Heart Journal. 126 (4): 1008–1011. doi:10.1016/0002-8703(93)90726-p.
^Wellfelt, K.; Sköld, A. C.; Wallin, A.; Danielsson, B. R. (1999-04-01). "Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species". Reproductive Toxicology (Elmsford, N.Y.). 13 (2): 93–101. ISSN0890-6238. PMID10213516.